Abliva AB (PK) Stock Price - NEVPF

0.116
0.003 (2.65%)
0.116
Best deals to access real time data!
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
Small Cap Pro
Monthly Subscription
for only
$49.05
Canna Trader Pro
Monthly Subscription
for only
$59.99
VAT not included
Company Name Stock Ticker Symbol Market Type
Abliva AB (PK) NEVPF OTCMarkets Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.003 2.65% 0.116 0.11 0.116 0.115 0.113 15:46:28
Bid Price Ask Price Spread Spread % News
0.116 0.16 0.044 27.5% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
5 43,732 $ 0.115588 $ 5,055 45,192 0.0597 - 0.31
Last Trade Time Type Quantity Stock Price Currency
13:53:16 33,200 $ 0.116 USD

Abliva AB (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 21.57M 185.95M 17.25M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
14.14k $ - 0.00% - -

more financials information »

Abliva AB (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NEVPF Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.110.160.10990.132001541,2200.0065.45%
1 Month0.0790.160.070.104172958,1180.03746.84%
3 Months0.07450.160.05970.098176848,9820.041555.7%
6 Months0.1390.1850.05970.103374628,949-0.023-16.55%
1 Year0.12650.310.05970.110095115,486-0.0105-8.3%
3 Years0.64470.66880.05970.149331710,245-0.5287-82.01%
5 Years2.702.700.05970.16880889,546-2.58-95.7%

Abliva AB (PK) Description

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. NeuroSTAT for traumatic brain injury is another clinical phase project. The R&D portfolio also consists of projects for mitochondrial myopathy, NASH and cancer. NeuroVive's ambition is to take drugs for rare diseases through clinical development and all the way to market, with or without partners. For projects for common indications the goal is out-licensing in preclinical phase. A subset of compounds under NeuroVive's NVP015 program was in 2018 licenced to Fortify Therapeutics, a BridgeBio company, for local treatment of Leber's Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).


Your Recent History
USOTC
NEVPF
Abliva AB ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.